6.62
price up icon2.00%   0.13
after-market Handel nachbörslich: 6.62
loading

Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten

pulisher
Oct 14, 2025

How to integrate Design Therapeutics Inc. into portfolio analysis toolsJuly 2025 News Drivers & Daily Technical Forecast Reports - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics - Yahoo Finance

Oct 14, 2025
pulisher
Oct 13, 2025

How Design Therapeutics Inc. stock reacts to global recession fearsTrade Analysis Summary & Safe Capital Allocation Plans - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Does Design Therapeutics Inc. fit your quant trading modelIndex Update & Risk Controlled Daily Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Is it time to cut losses on Design Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Published on: 2025-10-10 09:52:08 - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Leading vs lagging indicators on Design Therapeutics Inc. performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Design Therapeutics Inc. a candidate for recovery playJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Design Therapeutics Inc. stock volume spike explainedJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Why Design Therapeutics Inc. stock is in analyst buy zone2025 Technical Overview & Low Drawdown Trading Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Published on: 2025-10-09 02:15:05 - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ong - PharmiWeb.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is Design Therapeutics Inc a good long term investmentInstitutional Buying Trends & Low Entry Investment Plans - earlytimes.in

Oct 06, 2025
pulisher
Oct 06, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent AnalysisResearchAndMarkets.com - Business Wire

Oct 06, 2025
pulisher
Oct 06, 2025

Design Therapeutics Inc. recovery potential after sell offFed Meeting & Real-Time Chart Pattern Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Should you hold or exit Design Therapeutics Inc. now2025 Technical Overview & Smart Investment Allocation Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Top chart patterns to watch in Design Therapeutics Inc.2025 Price Targets & Free Verified High Yield Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

Analyzing Design Therapeutics Inc. with multi timeframe chartsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Risk adjusted return profile for Design Therapeutics Inc. analyzedEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why Design Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Smart Swing Trading Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire

Oct 02, 2025
pulisher
Oct 02, 2025

Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design - PR Newswire Canada

Oct 02, 2025
pulisher
Oct 01, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape - 24matins.uk

Oct 01, 2025
pulisher
Sep 30, 2025

Design Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Low Cost Stock Picks - earlytimes.in

Sep 30, 2025
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):